Company Human Metabolome Technologies, Inc.

Equities

6090

JP3794530000

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 02/05/2024 BST			5-day change	1st Jan Change
645 ^JPY	-0.77%		-2.57%	+0.78%

2023	Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2024	CI
2023	Human Metabolome Technologies, Inc. Reports Earnings Results for the Nine Months Ended March 31, 2023	CI

Human Metabolome Technologies, Inc. is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions. The Company operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.

JPY in Million	2022	Weight	2023	Weight	Delta
Advanced Research and Development Support 96.3 %	1,220	99.8 %	1,252	96.3 %	+2.57%
Healthcare Solutions 3.7 %	3	0.2 %	47	3.7 %	+1,562.71%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 83.1 %	1,032	84.3 %	1,080	83.1 %	+4.71%
Europe 12.8 %	152	12.4 %	167	12.8 %	+9.41%
Asia Pacific 4.0 %	39	3.2 %	52	4.0 %	+33.06%

Managers	Title	Age	Since
Katsuhito Hashidzume PSD	President	55	28/02/18
Tomomi Ishihara ADM	Chief Administrative Officer	-	-
Takaomi Fukuhara CTO	Chief Tech/Sci/R&D Officer	-	-
Midori Mizutani BRD	Director/Board Member	43	31/05/15
Junichi Matsuda BRD	Director/Board Member	64	31/05/15
Masatoshi Nakamura SAM	Sales & Marketing	-	-
Atsushi Nagashima PRN	Corporate Officer/Principal	49	30/06/05

Members of the board	Title	Age	Since
Yasuhiro Ohata BRD	Director/Board Member	59	30/06/20
Atsushi Nagashima PRN	Corporate Officer/Principal	49	30/06/05
Toshio Nagae BRD	Director/Board Member	80	23/06/17
Junichi Matsuda BRD	Director/Board Member	64	31/05/15
Midori Mizutani BRD	Director/Board Member	43	31/05/15
Katsuhito Hashidzume PSD	President	55	28/02/18
Hajime Natsukari BRD	Director/Board Member	44	21/09/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	5,915,733	4,765,489 ( 80.56 %)	144 ( 0.002434 %)	80.56 %

Name	Equities	%	Valuation
Masaru Tomita 6.593 %	390,000	6.593 %	2 M ¥
M3, INC. 3.670 %	217,100	3.670 %	939 578 ¥
Tomoyoshi Soga 3.516 %	208,000	3.516 %	900 195 ¥
Kaichi Nitta 3.381 %	200,000	3.381 %	865 572 ¥
DAI-ICHI LIFE HOLDINGS, INC. 3.146 %	186,100	3.146 %	805 415 ¥
THE YAMAGATA BANK, LTD. 2.536 %	150,000	2.536 %	649 179 ¥
FIDEA HOLDINGS CO. LTD. 2.536 %	150,000	2.536 %	649 179 ¥
Takaaki Nishioka 2.536 %	150,000	2.536 %	649 179 ¥
BOURBON CORPORATION 1.100 %	65,100	1.100 %	281 744 ¥
NISHIKAWA KEISOKU CO., LTD. 0.5071 %	30,000	0.5071 %	129 836 ¥

Name	Equities	%	Valuation
HUMAN METABOLOME TECHNOLOGIES, INC. 0.00%	100	0.00%	433 $

Human Metabolome Technologies, Inc.

246-2 Mizukami Kakuganji

997-0052, Tsuruoka

http://humanmetabolome.com

address Human Metabolome Technologies, Inc.(6090)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
HUMAN METABOLOME TECHNOLOGIES, INC.	+0.78%	24.4M
MODERNA, INC.	+26.56%	42.68B
IQVIA HOLDINGS INC.	-3.08%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.89%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-20.59%	18.96B
MEDPACE HOLDINGS, INC.	+29.04%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.61%	11.95B
BIO-TECHNE CORPORATION	-1.31%	11.55B

Other Biotechnology & Medical Research